raltegravir Methyl ester impuriy

Raltegravir Methyl ester impurity is a synthetic byproduct arising from esterification of the carboxylic acid moiety in the parent drug raltegravir. It retains the bicyclic naphthyridine-pyridine core with a methoxyethyl side chain, where the terminal carboxylic acid is converted to a methyl ester via methanol coupling. This structural modification alters its hydrolytic stability and chromatographic behavior compared to the API. It serves as a critical HPLC reference standard for quantifying process-related esterification impurities in raltegravir formulations.